Cytogen
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Cytogen develops technology that isolates living circulating tumor cells, cancer cells that travel through a patient's bloodstream, and uses them to help detect cancer, guide treatment choices, and monitor patient outcomes without a traditional tissue biopsy.
Its core platform, called Smart Biopsy™, provides analytical services and biomarker data to pharmaceutical companies developing new cancer drugs, supporting each stage from early-stage biomarker discovery through companion-diagnostic development. Research institutions also receive analysis data, kits, and collaborative research services. The company is listed on KOSDAQ, South Korea's tech-focused small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Cytogen in five facts
What does Cytogen do?
Cytogen develops technology that isolates living circulating tumor cells, cancer cells that travel through a patient's bloodstream, and uses them to help detect cancer, guide treatment choices, and monitor patient outcomes without a traditional tissue biopsy.
Where is Cytogen listed and in which sector?
Cytogen (Korean name: 싸이토젠) trades under KRX code 217330 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Cytogen?
Its market capitalisation was US$46.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Cytogen's latest annual revenue and operating profit?
For fiscal year 2025, Cytogen reported revenue of US$19.7M, an operating loss of US$6.2M and a net loss of US$9.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 138.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed (voluntary)
Cytogen updated a previously disclosed supply contract, now worth US$790K, about 9.62% of its recent annual revenue, running through Dec 2026.
Supply contract · Oct 20 - Report on large shareholdings (5% rule) (standard)Oct 12
- Report on securities held by executives/major shareholdersOct 12
- Report on large shareholdings (5% rule) (standard)Oct 12
- Completion report on merger, etc. (merger)
Cytogen Co., Ltd. completed its small-scale absorption merger of wholly owned subsidiary GenomeCare Co., Ltd. effective October 1, 2026, with a merger ratio of 1:0 and no new shares issued; 963 shareholders filed objections covering 236,678 shares (1.02% of total issued shares), and no creditor objections were received.
M&A · Oct 1 - Report on large shareholdings (5% rule) (standard)Sep 2
- Report on securities held by executives/major shareholdersSep 2
- Report on large shareholdings (5% rule) (standard)Sep 2
- DisclosureAug 31
- [Attachment amended] Material event report (merger)M&A · Jul 30
- Material event report (merger)
Cytogen decided to absorb-merge its wholly owned subsidiary GenomeCare Co., Ltd. (prenatal/infertility genomic diagnostics) in a small-scale, no-new-share merger (ratio 1.0000000:0.0000000), with a merger date of 2026-10-01 and registration expected 2026-10-15; GenomeCare reported 2025 total assets of US$6.62M, sales of US$7.6M, and net income of US$1.86M.
M&A · Jul 29 - Material event report (convertible bonds)
Cytogen disclosed convertible bonds to raise US$3.48M, about 7.2% of its market value.
Capital raise · May 18 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 23
- [Amended] Material event report (convertible bonds)
Cytogen updated the terms of convertible bonds to raise US$6.62M, about 13.5% of its market value.
Capital raise · Apr 23 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 20
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Cytogen reported consolidated results for FY2025: revenue of US$18.1M (+138.8% year on year), an operating loss of US$5.66M and a net loss of US$8.56M.
Earnings · Feb 13